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Examining the hypothesis that polycystic
kidney disease (PKD) is an emerging infectious
disease and/or microbial toxicosis in a vulnerable
population of humans must begin with a review
of the conceptual tools that relate disease etio-
logy and progression to the identification of
microbes, their cellular components, and shed
toxins in affected persons (1). An emerging infec-
tious disease can be defined, in part, as an existing
disease for which microbes are newly recognized
as a causative factor and/or as a factor contri-
buting to disease progression. The microbe may
be 1) present at the site of a lesion, 2) dissemi-
nated throughout the body, or 3) localized to an
anatomic site separate from the primary lesions.
In this third case, one or more toxins released by
the microbe into distribution fluids, usually
blood, produce the pathologic effect(s); this pro-
cess resembles microbial toxicosis, where the
patient is exposed only to the toxin(s) present in
the diet, environment, and gut microflora. Dis-
tinguishing between an infectious disease and
microbial toxicosis is essential if the source of the
toxin is to be removed or reduced. Concurrent
infection and microbial toxicosis (e.g., endo-
toxicosis, mycotoxicosis) can also occur. Although
mycotoxicosis is commonly understood to refer to
the absorption of small organic fungal toxins,
such as aflatoxin, fumonisin, or trichothecene,
detection of toxin in body fluids and tissues is
often difficult. Exposure to toxin may be episodic.
For many known and newly discovered microbial
toxins, analytical methods pertinent to the levels
of toxins involved in acute and chronic disease,
especially in vulnerable subpopulations, need to
be developed and verified in human tissues and
fluid. We have taken the view that the presence of
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Polycystic kidney disease (PKD) is one of the most common genetic diseases in
humans. We contend that it may be an emerging infectious disease and/or microbial
toxicosis in a vulnerable human subpopulation. Use of a differential activation protocol
for the Limulus amebocyte lysate (LAL) assay showed bacterial endotoxin and fungal
(1ﬁ3)-b-D-glucans in cyst fluids from human kidneys with PKD. Fatty acid analysis of
cyst fluid confirmed the presence of 3-hydroxy fatty acids characteristic of endotoxin.
Tissue and cyst fluid from three PKD patients were examined for fungal components.
Serologic tests showed Fusarium, Aspergillus, and Candida antigens. IgE, but not IgG,
reactive with Fusarium and Candida were also detected in cyst fluid. Fungal DNA was
detected in kidney tissue and cyst fluid from these three PKD patients, but not in healthy
human kidney tissue. We examine the intertwined nature of the actions of endotoxin
and fungal components, sphingolipid biology in PKD, the structure of PKD gene
products, infections, and integrity of gut function to establish a mechanistic hypothesis
for microbial provocation of human cystic disease. Proof of this hypothesis will require
identification of the microbes and microbial components involved and multifaceted
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signature components of microbial genera/species
that produce toxins may indicate that all compo-
nents of the microbe, including its shed toxins, are
also present. As a corollary, absorption of the de-
tectable microbial components, which are often lar-
ger in molecular size than the classical mycotoxins
and endotoxins, should presume the absorption of
other components and toxins from this organism.
On its face, PKD would not appear to be an
emerging infectious disease. Classically viewed as
an inherited disease that follows Mendelian
genetics, PKD in its autosomal dominant form
affects 600,000 people in the United States at a
rate of 1 in 400-1,000 persons; the autosomal
recessive form occurs in 1 per 44,000 births. An
acquired form of PKD occurs in patients on renal
dialysis. Animal models of inherited and chemi-
cally induced PKD have been described (2-4). The
current consensus is that fundamental anomalies
in cell differentiation or maturation explain the
array of anomalies in cystic renal epithelium.
Although cysts can sometimes be detected in
utero, loss of kidney function to the point of end-
stage renal disease occurs by the sixth decade in
50% of autosomal-dominant PKD patients. Despite
substantial progress in molecular genetics studies
of PKD, the role of defective gene products in its
causation and progression to end-stage renal
disease has remained elusive (3,5,6). Indeed,
additional factors have been proposed as being
necessary for progression of PKD to end-stage
renal disease. PKD patients have higher rates of
renal and urinary tract infections and higher
rates of illness and death from infection in
general than healthy persons (7,8). Since these
infections in otherwise-healthy-persons do not lead
to PKD, PKD patients could be exhibiting
heightened vulnerability to infection and sensiti-
vity to microbial cell components and toxins. How
such sensitivity and vulnerability might occur is
unknown. The disease does not appear to involve
an immunocompromised state. Thus, alternative
possibilities need to be considered, such as
altered colonization of the uroepithelium and
altered bowel structure and colonization.
Microbes and Microbial Components
Werder et al. (9) performed perhaps the
critical experiment in establishing a pathogenic
role for microbes in PKD. Using genetically cystic
mice, they found that mice grown under germ-
free conditions survived substantially longer than
cystic littermates grown under ambient conditions.
Gardner et al. (10,11) extended these observations
when they reported that rats fed a chemical
cystogen also had lower rates of renal cystogenesis
when raised under germ-free conditions; more-
over, coadministering the ubiquitous cell wall
component of gram-negative bacteria, lipopoly-
saccharides (LPS), and the chemical cystogen
produced higher rates of cyst formation than
using cystogen alone. Thus, LPS was considered
a provocateur of the underlying genetic (or
chemically induced) susceptibility to renal cysto-
genesis. From this line of research has emerged
the possibility that LPS, either alone or in
combination with other microbial or environ-
mental factors, promote disease progression, and
removal of such provocateurs would slow the
progression of PKD to end-state renal disease.
Endotoxin is the mixture of LPS and other
bacterial cell wall proteins and constituents that
is found in bacterial infections (12). LPS is
isolated by solvent extraction of bacterial cell
walls; its chemical purity may vary across
preparations. The portion of LPS responsible for
most of its known biological activities is Lipid A;
the carbohydrate side chains also elicit responses
in humans (13). The chemical composition of LPS
depends on the genera and species of bacteria
from which it is isolated (13,14). As knowledge of
the structure and biological activities of LPS has
increased and merged with the infectious disease
vocabulary based on endotoxin, these terms are
sometimes used interchangeably. For example,
the highly purified LPS used as positive reference
material in the Limulus amebocyte lysate (LAL)
assay is called Control Standard Endotoxin.
Even though interchanging the terms LPS and
endotoxin may promote appreciation of microbial
involvement in disease, we prefer the term
endotoxin in discussing disease because it re-
spects the structural and pharmacologic hetero-
geneity of LPS and mixtures of other microbial
components present in vivo.
When Miller et al. (15) measured putative
endotoxin levels by the classic LAL assay in
culture-negative urine samples of male PKD
patients with no clinically apparent infection,
80% contained detectable LAL-positive material,
while the urine samples of healthy male volun-
teers did not. In cyst fluid from PKD patients,
Gardner et al. (16) reported LAL-positive material
and cytokines typically induced by LPS. The
origins of the renal and urinary endotoxin were
not known; possible sources include the gut115 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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microflora, occult urogenital infections, cryptic
colonizations, and abnormal handling by the liver
of the normal daily load of absorbed endotoxin.
Enhanced exposure to endotoxin in the PKD
patient is important since endotoxin plays a
fundamental role in human health and disease.
In low doses, endotoxin enhances the immune
system, but in larger amounts it is lethal. In
combination with drugs and other substances, it
can cause tissue damage and severe disease;
examples of endotoxin synergy with other
substances resulting in disease include alcohol in
cirrhosis, aspirin in Reyes syndrome, and tricho-
thecene T-2 toxin (a mycotoxin from Fusarium) in
gastrointestinal tract damage (17). Endotoxin
can also promote the translocation of bacteria
from the gut into the blood (18). In susceptible
persons, chronic exposure to endotoxin has been
linked to rheumatoid arthritis (19); tentative
links with atherosclerosis have also been reported
(20). Although suggestive of endotoxin in PKD,
the LAL methods used above were not specific for
endotoxin, since they were susceptible to false
positive and/or negative results.
Bacterial Endotoxin in Human
PKD Renal Cysts
In this report, we describe our recent
findings concerning 1) endotoxin levels recorded
after recent improvements in LAL methods, 2)
analysis of fatty acids specific for bacterial
endotoxin, and 3) the presence of other microbial
components in human cyst fluid. The LAL assay
(Figure 1) is the classic method used to detect the
low levels of endotoxin in biologic fluids and
pharmaceuticals.
Both endotoxin (in eight of eight patients)
and (1ﬁ3)-b-D-glucans (in two of eight patients)
were detected when methods based on differential
activation of the two Limulus pathways were
applied to cyst fluids from six autosomal-domi-
nant PKD patients, one autosomal-recessive PKD
patient, and a patient with simple cysts, where
200 ml from a single simple cyst were recovered
(Table 1). None of these patients exhibited clini-
cal evidence of infection, had been on hemodialysis,
or received human immunologic products before
nephrectomy, which could have accounted for ß-
D-glucan reactivity (26). For six patients (four
autosomal dominant, one autosomal recessive,
and one with simple cysts), only endotoxin was
detected in cyst fluids; gel clot end points for both
the LAL and LAL+laminarin assays were equal
for each fluid tested,   indicating that the b-D-
glucan stimulated pathway was not activated.
When exposed to polymyxin B, LAL-positive cyst
fluids became negative. This is consistent with
the conformational changes that occur when this
antibiotic binds to Lipid A to form a stoichiometric
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Figure 1. Cascade of biochemical interactions and
reactions leading to gel clot formation in the Limulus
amebocyte lysate assay. Endotoxin binding to Factor C
via the Lipid A moiety results in its activation and in
turn the sequential activation of Factor B, which
results in the subsequent activation of the proclotting
enzyme. Binding of polymyxin B to endotoxin blocks
Limulus reactivity in those samples where endotoxin
is the initiating molecule. In contrast, (1ﬁ3)-b-D-
glucans bind to a different component, Factor G, in the
Limulus assay reagent, thereby leading to its
activation and subsequent cascade of reactions to gel
formation. The addition of laminarin, an inhibitor of
glucan binding to Factor G, to Limulus assay reagent
blocks reactivity of samples containing glucan (21).
Lipid A binds to and activates Factor C resulting
in a cascade of enzymatic reactions leading to gel clot
formation, the positive endpoint (22). Also present in
the classic LAL reagents is Factor G, which is
responsible for a side cascade (i.e., the alternative
pathway). Factor G is stimulated by (1ﬁ3)-ß-D-
glucans, associated primarily with fungal cell walls
(23). Addition of laminarin, an inhibitor of glucan
binding to Factor G (24), permits a more specific
measurement of endotoxin-induced gel clot formation
and provides a means of screening for (1ﬁ3)-b-D-
glucans in biological samples, when used in a
differential activation protocol with other inhibitors
and activators. As two internal controls, polymyxin B
can block the LAL reactivity of endotoxin (25), and
known quantities of Control Standard Endotoxin can
be added to duplicate samples to detect inhibition of
the assay.116 Emerging Infectious Diseases Vol. 3, No. 2, April–June 1997
Synopses
Table 1. Limulus assay results from human kidney cyst fluids
No. Cysts Cysts ET positive (%): Cysts ß-D-glucan
Donor No. Patient data Tested Endotoxin units/mla positive (%): pg/ml
1 ADb 45 yr F 5 3 (60%):  0.48 EU/ml ndc
2 AD 52 yr F 6 4 (67%):  1.71 EU/ml nd
3 AD 48 yr M Ld 9 5 (56%):  1.45 EU/ml nd
Re 11 6 (55%):  2.27 EU/ml nd
4 AD 41 yr F 16 3 (19%):  0.88 EU/ml 3 (19%): 120 pg/ml
5 AD 37 yr M 11 2 (18%):  3.84 EU/ml 6 (55%): 106 pg/ml
6 PDf AD 43 yr F 13 4 (31%):  0.26 EU/ml nd
7 ARg 5 wk M pool(8) 3.84 EU/ml nd
8 SCh 48 yr F 1(200ml) 3.84 EU/ml nd
aMean EU/ml or pg (1ﬁ3)-b-D-glucan/ml
bAutosomal-dominant polycystic kidney disease (PKD)
cNot detected
dLeft kidney
eRight kidney
fPeritoneal dialysis
gAutosomal recessive PKD
hSimple kidney cyst (not PKD)
Kidneys were from seven patients who had received or were awaiting renal allografts. Cyst fluid was obtained ex vivo
from both surface (cortex) and sub-surface (medullary) cysts by aseptic aspiration from seven excised kidneys (post-
nephrectomy) of PKD patients; simple cyst fluid was recovered by radiologically guided needle aspiration. All kidneys and cyst
fluids were collected under an approved Institutional Review Board protocol. The mean number of cysts aspirated per kidney
was 10 (range 1-21); two kidneys were obtained from one of the patients with both being used for studies. Fluid from individual
cysts in each kidney were collected separately, except for the autosomal-recessive PKD patient in whom cyst volumes were too
small (~ 0.1 ml) for individual testing. Therefore, fluid from eight cysts in close proximity were pooled.  All procedures used
pyrogen-free materials in the collection, handling, and processing of kidneys and cyst fluids and preparation of commodities
and reagents for the Limulus assay. Depyrogenation was carried out at 250°C for 4 hours, which eliminates both endotoxin and
(1ﬁ3)-ß-D glucans (27). Cyst fluids were stored at -70°C. Assessment parameters of cysts included color and size; for fluids,
color, turbidity, pH, mg protein/ml, specific gravity, and blood. A commercial dipstick was used to detect and semiquantitate
cyst fluid pH, specific gravity, and blood (Ames 10 SG Multistix, Miles, Inc., Elkhart, IN, USA). Blood sensitivity was 0.015-
0.062 mg/dL hemoglobin, equivalent to 5-20 intact red blood cells per microliter. Results were recorded as 1-4+. For specific
gravity, determinations permitted ranged from 1.000-1.030; for pH, 5.0-9.0. Protein was by the method of Lowry et al. (28).
The LAL gel clot end point assay (22) was performed according to the manufacturer’s instructions (Charles River
ENDOSAFE, Charleston, SC). The mechanism of the LAL assay is illustrated in Figure 1. To quantify endotoxin, undiluted
samples and serial twofold dilutions through 1:64 were tested. To detect false positives due to activation of the alternate (1ﬁ3)-
b-DG pathway, LAL assay reagent fortified with the glucan inhibitor laminarin was used (23). Laminarin was courtesy of Dr.
J. Cooper, Charles River ENDOSAFE, Charleston, SC. Laminarin had been rendered endotoxin free by treatment with 0.2 N
NaOH at 50°-60°C for 6 hours; treatment did not affect activity of laminarin in the LAL assay (23). The standard gel clot end
point method was used, except laminarin was added to the LAL assay reagent (23). Minimum sensitivity of both assays was
0.03-0.06 Endotoxin Units (EU)/ml (3-6 pg control standard endotoxin, CSE; 10 EU/ng of EC-5 (E.coli O133) U.S. Standard
endotoxin; for b-DG, ³10 pg/ml (29).
Known endotoxin-positive (tap water) and -negative (pyrogen-free water) samples were run as controls along with a CSE
curve. The endotoxin concentration was estimated by multiplying the maximum dilution producing a positive test against the
sensitivity of lysate that was verified daily. The content of b-DG in cyst fluid was estimated by the difference in titers between
the endotoxin specific assay (LAL+laminarin) and the conventional LAL assay (30). Portions of all samples were additionally
spiked with 0.25 EU CSE and tested for inhibitory substances. If inhibition was observed in the LAL assays, samples were
boiled for 5 minutes, cooled to room temperature, and retested. Samples were incubated, in some cases after boiling, for 30 min
at room temperature with polymyxin B (5 mg/assay) before LAL testing. Polymyxin B inhibits the LPS-activated pathway via
Factor C by its direct binding to LPS, which yields a nonreactive complex (25). An alternative approach was to use 20% dimethyl
sulfoxide (DMSO) to inhibit Factor C directly (23); DMSO was not used to permit detection of nonendotoxin, but LAL-reactive
materials that were not inactivated by binding to polymyxin B. However, in our system DMSO did completely block the LAL
reaction in the presence of CSE.
After centrifugation of the cyst fluid, the LAL-positive material was located only in the supernate for autosomal-
recessive- and simple cyst-derived fluids. For autosomal dominant-derived fluids, the reactive material was located in the
pellet. Thus, centrifugation of fluids to remove particulate material before the LAL assay may influence results.
LAL assay inhibition was detected in nearly two-thirds of 73 cyst fluids tested, including autosomal recessive and simple
cyst fluids. Dilution of cyst fluid through 1:16 was often required to overcome the inhibitory effect in unboiled specimens.
Boiling of entire fluids or supernates and pellets for 5 minutes eliminated LAL assay inhibition in virtually all specimens at
all dilutions. Exceptions were some undiluted and 1:2 dilutions of chocolate-colored cyst fluids, where inhibition was not
eliminated in both test and spiked specimens of autosomal dominant fluids.117 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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complex that is inactive in the  assay (25). In
contrast, kidney tissue from one male patient
(donor 4) and one female patient (donor 5) yielded
cyst fluids that contained separately endotoxin or
b-D-glucan; however, no single fluid contained
both substances (Table 1). Fluids that were LAL
positive in the presence or absence of polymyxin
B, but negative in the presence of laminarin are
consistent with the detection of b-D-glucan.
Donor 6 had been on peritoneal dialysis for slightly
more than 1 year before nephrectomy. Although
cyst fluids were all initially LAL negative, when
the incubation time of the LAL assay was increased
from 1 to 2 hours, 4 of 13 cyst fluids were endotoxin
positive, albeit at much lower concentrations
than the fluids from patients not on dialysis.
None of the cyst fluids from donor 6 were positive
for b-D-glucan after longer incubations. Longer
incubation times might also have produced LAL-
positive material in LAL-negative cyst fluids
from the other donors; therefore, we view the
percentage of LAL-positive cyst fluids for each
patient as a minimum value.
The concentrations of endotoxin-specific
material in autosomal dominant cyst fluids was
0.12 to 3.84 EU/ml, with substantial levels of
endotoxin (3.84 EU/ml) also found in a pool of
eight cysts from one autosomal recessive kidney
and simple cyst fluid from one donor. The mean
concentration of endotoxin across all of the auto-
somal dominant fluids tested (including those
that were LAL negative) was 0.65 EU/ml. Using
10 EU/ng as a conversion factor yields 65 pg
endotoxin/ml cyst fluid; normal plasma levels of
endotoxin are <4-5 pg/ml (31). Intravenous injec-
tion of 5 EU/kg body weight (350 EU/70 kg) can
induce shock in the average adult male (21). We
estimate that a single cystic kidney in an adult
male (3-5 kg kidney weight of which 33% is cyst
fluid) contains 648 to 1,080 EU/kidney or about
two lethal doses of endotoxin per kidney. Unex-
plained fever and flank pain in PKD patients
have been attributed to release of IL-1 from
rupture or hemorrhage of cysts (27). On the bases
of the high levels of endotoxin observed in this
study and the high sensitivity of humans to endo-
toxin, we propose that the release of endotoxin
from the cyst into the peritoneum or blood may be
an important initiator of a cascade of biologic
events after leakage or rupture of renal cysts.
For one donor (donor 3) both kidneys were
available for cyst fluid analysis (nine left and 11
right kidney cysts, respectively). When the
frequency of LAL-positive fluids (endotoxin) was
compared, no significant difference was found
(Table 1). However, a threefold difference in the
frequency of inhibitor detection was observed in
left kidney cyst fluids compared with the right
kidney (90% vs. 31%, respectively). Thus, LAL
testing of fluids for endotoxin requires vigilance
for both false negative and positive materials.
Signature Bacterial Fatty Acids
If endotoxin is present in renal cysts, fatty
acids unique to endotoxin can be used to confirm
its presence. The Lipid A region of LPS contains
on average four 3-hydroxy (3-OH) acyl groups of
various chain lengths (13,14). Acid hydrolysis of
LPS releases the 3-OH fatty acids and other fatty
acids. Diverse bacterial genera exhibit charac-
teristic ratios of fatty acids of various chain
lengths and patterns of hydroxylation; compila-
tions of such signature fatty acid profiles are
available for many genera (14). Initially, aliquots
of five cyst fluids were analyzed in a single blind
manner by gas chromatography-mass spectro-
metry as described by Mayberry and Lane (32). 3-
Hydroxy (3-OH) fatty acids of nC:12:0 and
nC:14:0 carbon length were detected but not
quantified in the three cyst fluids that were
positive in the endotoxin specific LAL assay; they
were not detected in the two cyst fluids that were
LAL negative. Thus, complete concordance of
LAL reactivity and signature fatty acid analysis
was observed. 3-OH fatty acids (C:14, C:16) were
also reported in LAL-positive cyst fluids by a
separate reference laboratory (Microbiological
Insights, Inc., Knoxville, TN). Additional chemical
analyses of cyst fluid are required before a classic
signature fatty acid profile and linkage to one or
more bacterial genera are possible. Also, we
cannot discount the possibility that 3-OH fatty
acids released during degradation of endotoxin
were incorporated into mammalian sphingolipids
that were positive in the LAL assay, thereby
accounting for both the presence of such fatty
acids and LAL reactivity in cyst fluids.
(1ﬁ3)-b b-D-Glucans (b b-DG)
In addition to endotoxin, (1ﬁ3)-b-D-glucans
were identified in cyst fluids from two patients by
differential activation of the LAL assay (Table 1).
The range of b-DG reactive material in cyst
fluids was estimated at 40 to 160 pg/ml. In plas-
ma of healthy persons, levels of b-DG are lower
than 6.9 pg/ml (26). b-DG, a ubiquitous constituent118 Emerging Infectious Diseases Vol. 3, No. 2, April–June 1997
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of filamentous fungal and yeast cell walls (33), is
exceeded only by endotoxin in its reactivity in the
LAL assay; glucans lacking a 1ﬁ3 linkage are not
LAL reactive (34), nor are mannans, dextrans,
and cellulose (24,26). Although diverse forms of
glucans are components of fungal cell walls, those
with (1ﬁ3)-b linkages are the most potent in
causing hypersensitivity pneumonitis and other
severe pulmonary illnesses (35). Although b-DGs
are indicative of fungal cell walls, their
occurrence alone does not identify the genera and
species of the fungus that produced it. To confirm
the presence of fungal components and determine
the source of b-DG, serologic tests were per-
formed on three b-DG positive and two b-DG
negative cyst fluids from three autosomal-domi-
nant PKD patients (Table 2). Cyst fluid from donor
6 that was negative for LAL-reactive material was
also free of detectable fungal antigens and anti-
from both kidneys containing b-DG-positive
material (donors 4 and 5; Table 1) were also
positive for fungal antigens. Fluid from donor 5
also exhibited fungal antibodies; fluid from donor
4 was not tested for antibodies to fungi.
Fungal serologic tests provided insights into
potential sources of b-DG. Initial measurements
showed Fusarium solani antigen. These findings
suggest the antigen to be from F. solani or a
shared antigen present in other Fusarium species
(L. Kaufman, pers. comm.). IgE (but not IgG)
antibody to  Fusarium moniliforme was also detected.
Aspergillus galactomannan antigen and Candida
albicans serotype A. mannan were present in
selected cyst fluids. Cross-reactivity of Fusarium
with Aspergillus and Penicillium is unlikely as 1)
the Fusarium antibody (prepared against the
mycelium) was cross-absorbed with Aspergillus,
and 2) the immunodominant group of Aspergillus
and Penicillium species, galactomannan with a
galactofuranosyl moiety (38), is absent in Fusarium
species (39). As the serologic tests for Fusarium
and Aspergillus in cyst fluids are experimental
and have not been evaluated clinically, these data
are indirect presumptive indication of the presence
of these fungal antigens. The paucity of fungal
serologic and chemical methods for detection and
identification of emerging fungal pathogens in hu-
man tissues and body fluids and fungal components
in the human diet has been noted by others.
Also detected were IgE antibodies to Can-
dida. IgE antibodies to both Fusarium and
Candida in cyst fluid suggest recruitment of
immunologic defenses against fungi. The site of
production of these IgEs and route of entry into
Table 2. Serologic results of five cyst fluids from three autosomal-dominant PKD patients tested for fungal
antigens or antibodies to fungal components
Donor;Cyst No. LALa Findings Serologic Findings
D6;1 Neg. Etb;Neg. ß-DGc Antigens not detected
D6;2 Neg. ET;Neg. ß-DG IgE and IgG reactive with fungi were not detected
D4;3 Neg. ET;Pos. ß-DG Antigens: Fusarium solani at 1:2 dilution; Aspergillus
galactomannan at >50 ng/ml
D5;4 Neg. ET;Pos. ß-DG Antigens: Aspergillus galactomannan at >50 ng/ml;
Candida albicans serotype A mannan at 10 ng/ml
D5;5 Neg. ET;Pos. ß-DG IgE reactive with Fusarium moniliforme; C. albicans
(weak positive)
aLimulus amebocyte lysate assay
bEndotoxin
cß-D-glucan
Fungal serology was performed on three cyst fluids from donors 4 and 5; (Table 1) with ß-DG positivity and two cyst fluids
from donor 6, which were negative for both endotoxin and ß-DG after extended incubation in the LAL assay. Fluids were tested
for antibody to Penicillium notatum (Penicillium chrysogenum) and Penicillium frequentans, Aspergillus fumigatus, Candida
albicans (yeast), and Fusarium moniliforme. The Pharmacia CAP systems RAST FEIA (IgE) and IgG FEIA were employed
(Pharmacia & Upjohn Diagnostics, Kalamazoo, MI, USA). The tests were modified by substituting cyst fluid for plasma;
interference of fluid with the test was not observed. Tests to detect fungal antigens were performed by the Centers for Disease
Control and Prevention, Atlanta, GA. To detect Fusarium sp. antigen, a modified aspergillosis microimmunodiffusion test (36)
was used with experimental rabbit anti-Fusarium solani antibody; kidney cyst fluid was substituted for plasma. A double-
antibody sandwich enzyme immunoassay was used to detect C. albicans serotype A mannan concentrations in cyst fluids;
specificity of this test in sera is reported as 100% (37). An experimental ELISA inhibition assay was used to detect Aspergillus
galactomannan (Steven Hurst, unpub. protocol) Standard serum reference curves were used for extrapolating quantities of C.
albicans mannan and Aspergillus galactomannan in cyst fluids. However, these tests were not designed for cyst fluids, but for
serum antigen detection, and must, therefore, be viewed as estimated quantities.119 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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the cyst are unknown; a hypersensitivity reaction
cannot be discounted. In human and experimental
PKD, the severity of cystic disease correlates
with the numbers of circulating neutrophils; neu-
trophilia is related to exposure to endotoxin and
cytokines, both of which have been reported in
cyst fluids (16). Our finding of fungal antigens
and antibodies raises the additional possibility of
leukocyte activation in PKD by ß-DG and mannan
released from fungi, as ß-DG and mannan have
been reported to stimulate cytokine production (40).
Serologic testing is frequently used to detect
fungal infection. Cyst fluids collected from PKD
patients at sequential times during progressive
stages of the disease were not feasible. Therefore,
quantitative and/or qualitative changes in anti-
gen or antibody titers could not be used to deter-
mine active fungal infections in these patients.
Although antigens of Aspergillus or Fusarium
species are generally interpreted as apparent or
covert infection, another possibility is the absorp-
tion and distribution of fungal components inde-
pendent of infection (i.e., mycotoxicosis versus
infection). While  Aspergillus enters primarily by
inhalation, this route does not appear to be the
predominant source of Fusarium; fewer than 1% of
air samples contained Fusarium species (41). Fu-
monisin from Fusarium is present in grains, rice,
and corn consumed by humans (42), with regional
variations in levels and the type and processing
of dietary product. Because of their occurrence in
the food supply and their effect on experimental
animals, it has been proposed that fumonisins
may contribute to kidney disease in humans (43).
ß-D-Glucans and mannans are shed by fungi
during growth (26,39) and thus, like bacterial
endotoxin, can potentially be distributed through
blood and lymph. Diverticular disease and other
anomalies in the structural and functional integ-
rity of the gut may occur in up to 80% of PKD
patients (2,44). In addition to diminished barriers
to the absorption of gut-derived endotoxin, the
outpouchings (diverticula) become overgrown by
minor subpopulations of gut microflora (45),
thereby generating increased quantities of un-
usual mixtures of potentially absorbable microbial
components. Diverticular disease (44) and ac-
quired renal cystic disease (46) occur in patients on
hemo- and peritoneal dialysis. To complete the
symmetry of this line of reasoning, outpouchings
of the renal tubule in PKD are described as both
cysts and diverticula (2). Direct measurement of
intracyst pressure and elasticity of the basal
lamina have led to the rejection of the obstruction
hypothesis (i.e., a physical balloon inflation) of
cystogenesis in favor of a cell-mediated restruc-
turing of the basal lamina coupled with electro-
lyte transport into the cyst to expand intracyst
volume (47). Although diverticular disease is
thought to be a pressure-driven lesion, gut diver-
ticula in PKD and dialysis patients may also
involve a cellular lesion further promoted by
pressure. Thus, diverticula in kidney and gut are
associated with microbial components. It is not
known if the processes of renal cystogenesis,
formation of gut diverticula, and the walling off of
infecting material are all facets of the same
defense response in humans. Endotoxin in rela-
tively high concentrations was found in fluid from
a simple cystic kidney (Table 1); intestinal or
biliary obstruction and urinary tract infections
have been associated with simple kidney cysts
(2). Although endotoxin has been proposed as
being associated with “high sodium cyst fluids”
(47), we observed endotoxin in cyst fluids of low
and high sodium content (data not shown).
Relevant to our study is the report of the
capacity of ß-DG to prime cell systems, which
results in sensitization to bacterial endotoxin
and infection (48), an example of ß-DG-endotoxin
enhancement; ß-DG and endotoxin also demon-
strate a strong synergistic effect on macrophages
(49). In addition, there have been reports of
synergy between mycotoxin and endotoxin (50).
Detection of Fungal DNA
To identify fungal DNA as evidence of past or
current fungal infection and/or the absorption
and distribution of fungal components to kidney
cysts, polymerase chain reaction (PCR) methods
were used to amplify and thus detect fungal DNA
in PKD cyst fluids and kidney tissue.  Six cyst
fluids from three patients and two samples of
kidney tissue from two autosomal-dominant
PKD patients were tested; all were positive for
fungal DNA. A sample of normal human kidney
was negative for fungal DNA (Figure 2 A-C).
Because culture confirmation was not achieved
from the cyst fluids, expanded studies with
species-specific probes are warranted.
Despite substantial effort, we have not been
able to culture either bacteria or fungi from PKD
cyst fluids by axenic methods, but fungi were
detected in cultured epithelial cells from PKD
kidney tissue (see below); methods appropriate to
culture L-forms or other cell-wall-defective microbes120 Emerging Infectious Diseases Vol. 3, No. 2, AprilJune 1997
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were not performed. Gram stains of cyst fluid
supernates and pellets did not show intact bac-
teria. Electron microscopy also did not show
intact bacteria, but occasionally, a field consis-
tent with fungal cell walls was observed (not
shown); intact fungi were not observed. Nonethe-
less, it was only from PKD kidneys where b-DG
was identified in cyst fluid that fungal organisms
were frequently isolated from PKD epithelial cell
cultures. Other human and animal cells isolated
and propagated in the laboratory by the same
reagents and work spaces were free of fungal
growth. The fungi were identified as belonging to
the genera  Paecilomyces and a new species of
Penicillium (manuscript in preparation). Fungi
have been reported, albeit infrequently, as etio-
logic agents in renal infections in PKD (8). Given
all of the above, it is possible that viable fungi
were present in the PKD renal tissue, but only
Figure 2. Amplification results of normal and PKD
kidney tissue and cyst fluids with universal fungal
primers ITS 1 and NL 4. 2A: DNA from healthy human
kidney tissue diluted 1:10, 1:100 and 1:1,000 (lanes 1-
3); control fungal DNA, A. tamarii (lane 4); negative
control (lane 5); 1 kb ladder (lane 6); arrow indicates
migration front. 2B (NL 4) and 2C (ITS 1): two cyst
fluids, donor 6, negative for detectable endotoxin and
b-DG (lanes 1 and 5); two cyst fluids, donor 4, positive
for b-DG (lanes 2 and 3) and positive for Fusarium
solani  antigen (lane 3); two cyst fluids, donor 5,
positive for b-DG (lanes 4 and 6); two PKD kidney
tissues, donor 5 (lane 7) and donor 4 (lane 8); negative
control (lane 9). Large arrows in 2B and 2C point to
560 bp molecular weight marker; small arrows point to
product bands.
Polymerase Chain Reaction
Specimens for PCR included 1) normal human kidney
tissue (0.46 g) from a 7-year-old girl who died of a head
injury; the kidney was not transplantable because of the
presence of a hematoma but was otherwise normal; the
section used for PCR excluded the area of hematoma. 2) 0.5 g
of cystic tissue, devoid of cyst fluid, from each of two
autosomal-dominant PKD patients (donors 4 and 5, Table 1).
3) multiple cyst fluids (0.5-1.0 ml each; donors 4, 5, and 6).
The positive control consisted of DNA extracted from A. tamarii
(NRRL 26010) plus primer. The CTAB extraction method for
fungal genomic DNA was employed. The universal
oligonucleotide primer pair ITS 1 and NL4 for fungi, as
previously described (51), was used; NL 4 is the reverse
primer. PCR master mix (37) with 1.5 mM MgCl2 and primers
in a final reaction volume of 100 ml was subjected to the
following thermal cycler parameters (Perkin Elmer Thermo
Cycler 1): 96°C30 sec; 53°C30 sec and 72°C30 sec for 40
cycles, followed by a final 7 min extension at 72°C and soak at
4°C. The presence of the expected molecular weight PCR products
(600 bp) was confirmed by ethidium bromide staining after
separation on a 1.0 % agarose gel. The amplified products were com-
pared visually for similarity on the basis of the presence or absence
of bands; variations in band intensity were not considered.
A-C represent the banding patterns obtained by
agarose gel electrophoresis of healthy kidney tissue, cystic
kidney tissues, and cyst fluids following PCR amplification
with the universal fungal primer pair, ITS 1 and NL 4.
Amplified fungal products were not detected in the negative
PCR controls (2A, lane 5; 2B and C, lanes 9) or normal human
kidney tissue (2A, lanes 1-3). In marked contrast, distinct
bands of the predicted size of each fungal primer used ( ~ 600
bp; 45) were detected in all cystic kidney tissues and fluids
examined from the three patients (2B-C); minor fragments
were not detected. The migration patterns were consistent
with the positive fungal DNA control (2A, lane 4).
Although fungal DNA might have been anticipated in
tissues and fluids from PKD kidneys showing b-DG or
positive serologic findings, fungal DNA was also found in
PKD cyst fluid from donor 6 (2B and C: Lanes 1 and 5), which
lacked these components. The b-DG positive cyst fluids
tested from donors 4 and 5 are in Lanes 2 and 3 and 4 and 6,
respectively. The fluid depicted in Lane 3 also had positive
serologic results for F. solani antigen; serologic testing was
not done on the other fluids assayed by PCR. Each cyst fluid
must be considered an independent sample, requiring direct
measurement; assumption of cyst content on the basis of
other fluids within the same kidney is not valid (16). Fungal
DNA was also detected in kidney tissue from donors 4 and 5
(Figure 2B and C; Lanes 8 and 7). Differences were noted
between the two primers used; ITS 1 yielded amplified
products in all PKD samples while NL 4 amplified less well,
being more concordant with the detection of b-DG.  The
amplicons are presumptive evidence of fungal DNA.121 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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their remnants were in the cyst fluid. Emerging
human awareness of infectious disease may well
describe our experience in this study of PKD.
Infectious Disease, Microbial Toxicosis,
and Sphingolipid Biology
Emerging knowledge of sphingolipid biology
and PKD’s vulnerability to microbial toxins offer
an opportunity for a fresh look at PKD. As Spiegel
and Merrill (52) have noted, sphingolipids fall
into two broad categories, both of which are altered
in PKD (53,54). Complex sphingolipids (i.e., cera-
mide with a carbohydrate or phosphocholine head
group on carbon-1) interact with growth factor
receptors and the extracellular matrix and adja-
cent cells and act as binding sites for gram-
positive and -negative bacteria and microbial
toxins. In the second category of sphingolipids,
ceramide sphingoid bases (i.e., sphingosine, sphin-
ganine, phytosphingosine) and their 1-phosphates
modify the activity of protein kinases and phos-
phatases, ion transporters, and a growing number
of signal transduction processes. However, the
dynamics of human sphingolipid biology occur within
the context of a microbe-dominated environment.
Thus, we propose a third category called
“microsphingoids,” sphingolipid-like molecules of
microbial origin that mimic or antagonize the
actions or metabolism of human sphingolipids.
Examples include, but are not limited to, various
mycotoxins (42,55-57), bacterial sphingolipids
(58), and endotoxin (59,60). In this report, we
have shown the presence of endotoxin and fungal
antigens or antibodies to at least Fusarium,
Aspergillus, and Candida in human PKD tissues
and fluids; from human PKD cells in vitro we
have encountered Paecilomyces and Penicillium.
These fungi produce mycotoxins that inhibit
multiple enzymes required for sphingolipid
biosynthesis (55; Figure 3) and alter the activity
of various elements of signal transduction cas-
cades, such as protein phosphatases, calmodulin,
and GTP-binding proteins (56,61). Such myco-
toxins are also found in the human diet, which is
itself an emerging concern in food safety
(42,43,55). Rietschel et al. (13) noted the simi-
larity of LPS to glycosphingolipids. Wright and
Kolesnick (59) have reviewed the structural
similarity of the Lipid A region of bacterial LPS
with ceramide and the ability of LPS to mimic the
ceramide-induced alterations in protein kinase
and phosphatase activities. Endotoxin is also
reported to alter the structure of mammalian
sphingolipids (62) and to initiate cytokine-mediated
cascades that generate ceramide, sphingosine-1-
phosphate, and lysosphingolipids, all of which
exhibit biologic activity (13,63). Not to be ignored
are bacterial sphingolipids formed by genera such
as Bacteriodes, which represent approximately
30% of the gut microflora (58). The role of bac-
terial sphingolipids and their metabolites in
human biology and their bioavailability in
disease are poorly understood. The term “micro-
sphingoid” is intended to highlight the contri-
bution of microbes to sphingolipid biology in
human health and disease.
Could pertubations in sphingolipid biology
caused by genetic anomalies and/or “micro-
sphingoids” account for both infantile autosomal
recessive and adult onset forms of kidney cystic
disease? Hannun (64) has reviewed the role of
sphingolipids as “biostats” that regulate diverse
cellular programs executed in response to
various stimuli. Such biostatic regulation could
account for both acute and chronic changes in
cellular behavior and differentiation in the kid-
ney (65). Calvet et al. (2,66) have proposed two
models to explain the immaturity or dedif-
ferentiated state of epithelial cells found in
hereditary and acquired cystic kidneys: In infan-
tile cystic disease, the epithelial cells never reach
terminal differentiation and are trapped in an
immature state, while in adult forms of cystic
disease, toxin-induced injury to an initially
mature renal epithelium is followed by inability
of the epithelium to recover to a fully differen-
tiated state. In genetically cystic cpk/cpk mice (a
model for autosomal recessive PKD), Deshmukh
et al. (53) reported altered levels of ceramide and
complex glycosphingolipids in kidney tissue from
cystic mice, but not in their phenotypically
normal littermates. Lower levels of ceramide and
sulfatide, but higher levels of glucosyl- and lacto-
sylceramide and ganglioside GM3, were measured.
Our research in infantile and adult human PKD
kidney tissue and cyst fluids showed no detec-
table free sphinganine, the primary sphingoid base
formed during de novo biosynthesis of mammalian
sphingolipids (54). Thus, anomalies in sphingolipid
biology exist in cystic kidney tissue.
It is difficult to separate concepts of
sphingolipid biology from considerations of infec-
tious disease, microbial components, and “micro-
sphingoids” in PKD. Potential consequences of
alterations in glycosphingolipids on the surface
of PKD cells include enhanced microbial122 Emerging Infectious Diseases Vol. 3, No. 2, AprilJune 1997
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Figure 3. Sites of impact of endotoxin and mycotoxins on sphingolipid metabolism. In PKD, renal sphingolipid
formation is altered. Such compromised sphingolipid pathways would be expected to be vulnerable to these highly
potent microbial toxins, especially during chronic exposure within renal cysts.123 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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colonization due to the availability of complex
sphingolipids as binding sites. Binding of microbes
or their components to such sphingolipids may
even promote cystogenesis, as binding to complex
sphingolipid has been reported to cause changes
in differentiation and morphology of cells in vitro
(67). Altered biosynthesis of sphingoid bases affects
the ratios of sphinganine to sphingosine with
consequences to signal transduction (61) and
may even alter the antimicrobial environment, as
sphingoid bases are reported to have direct
antifungal and antibacterial activity (68). The
levels of sphingosine in human cyst fluid (Hjelle,
unpub.) are comparable to the levels that induce
a state of cytoresistance (cellular dedifferen-
tiation) in kidney cells in vitro (69). In addition to
products of mammalian sphingolipid metabolism,
endotoxin in relatively high amounts was found
in cyst fluids from infantile and adult forms of
PKD and in simple cysts (Table 1). Could “micro-
sphingoids” or microbial toxins injure and then
prevent repair of renal epithelial cells? Data from
diverse scientific disciplines support this possibility.
LPS influences nephron formation (70) and
renal cystogenesis (11). Fumonisins are potent
nephrotoxins (43,55), alter repair mechanisms in
kidney cells in vitro (71), and induce apoptosis
(72,73). Renal cysts are occasionally reported after
chronic exposure of rodents to fumonisins (74).
Rates of programmed cell death are abnormal in
PKD kidney tissue (75,76); ceramide is a pivotal
messenger in apoptosis (64). In PKD, altered
processing and sorting of cell membrane proteins
and secretory material occurs (2-4); sphingolipids
influence processing, sorting, and movement of
membranes and ion transporters (64,65), as does
fumonisin in kidney cells in vitro (77). In PKD,
various electrolyte transport systems are altered
(2). cAMP-mediated electrolyte fluxes were pro-
posed as important in cyst formation (3).
Fumonisins are reported to activate cAMP
response elements (78). Cyst fluid contains uncha-
racterized substances that promote cystogenesis
in vitro (3). Although LPS isolated from
Escherichia coli did not induce the full array of
anticipated cystogenic responses in kidney cells
in vitro, the structure, potency, and array of
elicited biologic responses of endotoxin depend on
the genera and species of bacteria from which it
was isolated (13). Coupled with the presence of
fungal components, cyst fluid likely represents a
complex mixture of “microsphingoids” and toxins
that may change over time with dynamic
consequences to cyst formation. The heterogeneity
of cyst volume and content of growth factors and
cytokines in adult PKD has been noted (3,16).
Concepts of infection and “microsphingoids”
appear to converge with the expanding knowledge
of PKD gene products. The structures of the
PKD1 (polycystin) and PKD2 gene products
share homology with a1E subtype of voltage-
activated, calcium channels (3,6) and a sea urchin
protein likely involved in calcium fluxes during
fertilization (79). LPS alters voltage-activated,
calcium channels (80) and osmo-regulation (81)
in mammalian cells. The PKD1 gene product also
contains regions of homology with ligand and
receptor domains putatively involved in binding
to adjacent cells and extra-cellular matrix (3);
one such domain is similar to C type lectins that
can bind microbes (82). Tissues, including kidney
and gut, expressing polycystin in adult PKD, may
exhibit a relatively greater leakiness to normal
molecular and par-ticulate traffic, as seen in kidney
cysts (3) and susceptibility to diverticulosis (3,44).
Polycystin also shows homology with apoprotein
from low density lipoprotein. Because LPS and
sphingo-lipids bind to and are transported by
serum lipoproteins, the low-density lipoprotein
binding site in polycystin may also enable
accumulation and/or transport of “microsphingoids.”
Secondary mutations in PKD genes appear
to be required for clonal cyst formation (3,5), as is
a loss of renal tissue through dysregulation of
apoptosis (76). Alterations in the expression of
the bcl-2 gene product in mice results in poly-
cystic kidneys and dysregulation of apoptosis
(83). Although infection increases translocation
of the bcl-2 gene in human lymphoid tissue (84), it
is not known if infection in PKD patients causes
such a dysregulation of bcl-2 in kidney tissue.
Regarding infection and sphingolipids, cera-
mide is emerging as a pivotal molecule in the
immune system (63) and fumonisins are reported
to alter immune function (85). It is ironic that our
findings potentially link Fusarium to PKD, as
fumonisin is used as a molecular tool to study
sphingolipid metabolism and signal trandsduction
in PKD. Not to be overlooked are the classic
bacterial sphingomyelinases encountered during
infection and released from gut microflora (e.g.,
Staphylococcus aureus and Clostridium perfringens)
that can stimulate ceramide formation by hydro-
lysis of sphingomyelin. Thus, the vulnerability of
PKD patients to infection may be related, in part,
to anomalies in sphingolipid biology that influence124 Emerging Infectious Diseases Vol. 3, No. 2, April–June 1997
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1) “biostatic” mechanisms of cell regulation, 2)
the structure of the plasma membrane and the
function of PKD gene products, 3) the availability
of glycosphingolipids as binding sites for microbes
and their components, 4) the bioavailability of
microbial components present in the gut, and 5)
antimicrobial defenses in general. Such vulnera-
bility is likely influenced by repeated courses of
antimicrobial therapy that provide selection pres-
sure for colonization with a modified microflora.
The extent to which sphingolipid biology in PKD
is influenced by  genetic defects rather than micro-
bial factors is yet to be defined.
Anomalies caused by the PKD gene defect(s)
alone cannot explain cystogenesis. As shown by
Werder et al. (9), raising genetically cystic mice
in a germ-free environment essentially eliminated
cystogenesis and increased survivorship to nearly
100% over that of littermates raised in ambient
environment for 18 months. Even in cyst fluid
from infantile PKD, relatively high levels of
endotoxin were found (Table 1). This suggests
that microbial toxins are available early in this
disease. Prenatal exposures to toxins and “micro-
sphingoids” are unknown. Although our finding
of fungal DNA in eight of eight samples of
autosomal-dominant PKD tissue and cyst fluids
examined suggests an intimate association of
fungal exposure to renal cysts, a contributing
multifaceted microbial toxicosis involving diet
and gut microflora cannot be excluded. By itself,
the finding of microbial components at the site of
lesion does not prove a causal role for the
microbe(s) in disease progression (1). However, a
working hypothesis can be formed on the basis of
evidence that microbes promote progression of
the primary disease and components of the
microbes act on mammalian biology to cause
effects plausibly related to the known patho-
physiology of the disease.
Although there is an established body of
knowledge that PKD is a genetic disorder, our
data indicate that bacterial endotoxin, ß-DG, and
likely other microbial components are available
within the kidney to provoke cystogenesis. We
have provided chemical and advanced LAL assay-
based evidence of bacterial endotoxin and ß-DG
in human PKD cyst fluids. From cyst fluids and
PKD kidney tissue we have provided evidence of
fungal DNA and cell components by serologic
testing and PCR with universal fungal primers.
We have integrated these findings into a working
hypothesis based on emerging knowledge of PKD
gene products, altered sphingolipid metabolism
in PKD, the effects of LPS on renal cystogenesis,
the mimicry of ceramide by LPS and the effects of
mycotoxins on mammalian sphingolipid biology
and signal transduction, the occurrence of infec-
tion in PKD, and the impact of altered gut
permeability and microbial colonization on pro-
gression of PKD. Is PKD a genetic disease
promoted by microbial influences? Tests of this
multifaceted hypothesis require awareness of a
breadth of issues drawn from numerous scientific
disciplines. Identification of the microbes and
microbial components involved will require a
concerted analysis using highly sensitive and
specific methods. As awareness of the importance
of sphingolipid biology in health and disease grows,
so will the appreciation that microbial influences
will need to be considered in pharmacologic
studies that seek to manipulate ceramide and
complex sphingolipid biochemistry in disease. The
ubiquitous and highly potent bacterial endotoxin
is again one of the usual suspects examined as
provocateur of disease; in this case, endotoxin’s
modus operandi of coopting the signal trans-
duction machinery of ceramide to cause chronic
disease may ultimately be revealed.
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